Trials / Sponsors / Oncopeptides AB

Oncopeptides AB

Industry · 10 registered clinical trials.

Status	Trial	Phase	Started
Withdrawn	A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Mye Relapse Multiple Myeloma, Multiple Myeloma	Phase 1	2021-05-27
Terminated	Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Mye Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma	Phase 3	2020-12-21
Terminated	A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light AL Amyloidosis	Phase 1	2020-08-06
Terminated	A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients RRMM	Phase 2	2020-08-04
Terminated	PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Fun Renal Impairment, Multiple Myeloma	Phase 2	2018-08-28
Terminated	Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM Multiple Myeloma	Phase 1 / Phase 2	2018-04-12
Terminated	A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidom Multiple Myeloma	Phase 3	2017-06-12
Completed	A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multip Multiple Myeloma	Phase 2	2016-12-28
Terminated	Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Pat Relapsed and/or Relapsed-refractory Multiple Myeloma	Phase 1 / Phase 2	2013-07-01
Approved For Marketing	Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma Relapsed and/or Refractory Multiple Myeloma	—	—